摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

copper(II) acetate monohydrate | 119821-91-9

中文名称
——
中文别名
——
英文名称
copper(II) acetate monohydrate
英文别名
copper;diacetate;hydrate
copper(II) acetate monohydrate化学式
CAS
119821-91-9
化学式
C4H6CuO4*H2O
mdl
——
分子量
199.651
InChiKey
NWFNSTOSIVLCJA-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.31
  • 重原子数:
    10
  • 可旋转键数:
    0
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    81.3
  • 氢给体数:
    1
  • 氢受体数:
    5

ADMET

毒理性
  • 副作用
职业性肝毒素 - 第二性肝毒素:在职业环境中的毒性效应潜力是基于人类摄入或动物实验的中毒案例。 肾毒素 - 该化学品在职业环境中可能对肾脏有毒。 高血红蛋白血症 - 血液中高血红蛋白含量增加;该化合物被归类为第二级毒性效应。 溶血性贫血 - 血红蛋白或红细胞数量减少。
Occupational hepatotoxin - Secondary hepatotoxins: the potential for toxic effect in the occupational setting is based on cases of poisoning by human ingestion or animal experimentation. Nephrotoxin - The chemical is potentially toxic to the kidneys in the occupational setting. Methemoglobinemia - The presence of increased methemoglobin in the blood; the compound is classified as secondary toxic effect Hemolytic anemia - Decreased hemoglobin or number of red blood cells.
来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

点击查看最新优质反应信息

文献信息

  • CARBORANYLPORPHYRINS AND USES THEREOF
    申请人:Wu Haitao
    公开号:US20050260128A1
    公开(公告)日:2005-11-24
    The present invention is directed to low toxicity boronated compounds and methods for their use in the treatment, visualization, and diagnosis of tumors. More specifically, the present invention is directed to low toxicity carborane-containing 5, 10, 15, 20-tetraphenylporphyrin compounds and methods for their use particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT) for the treatment of tumors of the brain, head and neck, and surrounding tissue. The invention is also directed to using these carborane-containing tetraphenyl porphyrin compounds to methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
    本发明涉及低毒性化合物及其在肿瘤治疗、可视化和诊断中的应用方法。更具体地说,本发明涉及低毒性的含有五、十、十五、二十-四苯基卟啉硼烷化合物及其在中子俘获疗法(BNCT)和光动力疗法(PDT)中的应用方法,用于治疗脑、头颈及周围组织的肿瘤。本发明还涉及使用这些含硼烷四苯基卟啉化合物进行肿瘤成像和/或诊断的方法,如MRI、SPECT或PET。
  • Tetraketone porphyrin monomers and the porphyrin-based polymers thereof
    申请人:General Petrochemical Industries Ltd
    公开号:US05091502A1
    公开(公告)日:1992-02-25
    The present invention relates to a tetraketone of the structure ##STR1## wherein M is a metal atom and R is selected from phenyl, alkyl substituted phenyl or halogen substituted phenyl. The process to prepare this tetraketone is disclosed. The present invention also relates to a process to produce the tetraketone structure(I). The present invention also relates to the novel polymer of the structure: ##STR2## and to the process to produce this novel polymer. R is as defined hereinabove, and Ar is a tetraamine substituted organic moiety having at least one aromatic ring. These polymers are useful as liquid crystals and in non-linear optical devices.
    本发明涉及一种结构为##STR1##其中M是属原子,R选自基、烷基取代基或卤素取代基。公开了制备这种四的过程。本发明还涉及一种制备四结构(I)的方法。本发明还涉及一种结构为##STR2##的新型聚合物,以及制备该新型聚合物的方法。其中R如上所述定义,Ar是至少具有一个芳香环的四胺取代有机基团。这些聚合物可用作液晶和非线性光学器件。
  • Anode active material, method of manufacturing the same, and lithium battery using the same
    申请人:Kim Han-su
    公开号:US20070077490A1
    公开(公告)日:2007-04-05
    Anode active materials, methods of producing the same and lithium batteries using the same are provided. More particularly, an anode active material having high capacity and excellent capacity retention, a method of producing the same and a lithium battery having a long lifespan using the same are provided. The anode active material comprises complex material particles comprising silicon and graphite, a carbon layer covering the surface of the complex material particles, and a silicon-metal alloy formed between the complex material particles and the amorphous carbon layer.
    本发明提供了阳极活性材料、其制备方法以及使用该材料的电池。更具体地,本发明提供了一种具有高容量和优异容量保持性能的阳极活性材料、其制备方法以及使用该材料的寿命较长的电池。该阳极活性材料包括复合材料颗粒,其中包含和石墨,层覆盖复合材料颗粒的表面,以及形成在复合材料颗粒和非晶层之间的属合
  • Copper CHA Zeolinte Catalysts
    申请人:Bull Ivor
    公开号:US20080226545A1
    公开(公告)日:2008-09-18
    Zeolite catalysts and systems and methods for preparing and using zeolite catalysts having the CHA crystal structure are disclosed. The catalysts can be used to remove nitrogen oxides from a gaseous medium across a broad temperature range and exhibit hydrothermal stable at high reaction temperatures. The zeolite catalysts include a zeolite carrier having a silica to alumina ratio from about 15:1 to about 256:1 and a copper to alumina ratio from about 0.25:1 to about 1:1.
    本发明公开了一种具有CHA晶体结构的沸石催化剂及其制备和使用方法。该催化剂可用于在广泛的温度范围内从气态介质中去除化物,并在高反应温度下表现出良好的耐热稳定性。沸石催化剂包括具有比约为15:1至256:1和比约为0.25:1至1:1的沸石载体。
  • Copper CHA Zeolite Catalysts
    申请人:Bull Ivor
    公开号:US20090285737A1
    公开(公告)日:2009-11-19
    Zeolite catalysts and systems and methods for preparing and using zeolite catalysts having the CHA crystal structure are disclosed. The catalysts can be used to remove nitrogen oxides from a gaseous medium across a broad temperature range and exhibit hydrothermal stable at high reaction temperatures. The zeolite catalysts include a zeolite carrier having a silica to alumina ratio from about 15:1 to about 256:1 and a copper to alumina ratio from about 0.25:1 to about 1:1.
    本发明公开了具有CHA晶体结构的沸石催化剂及其制备和使用方法。该催化剂可用于在广泛的温度范围内从气体介质中去除化物,并在高反应温度下表现出耐热稳定性。该沸石催化剂包括一个沸石载体,其比约为15:1至256:1,比约为0.25:1至1:1。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,4R)-Boc-4-环己基-吡咯烷-2-羧酸 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-N,3,3-三甲基-N-(苯甲基)丁酰胺 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S)-2-氨基-3,3-二甲基-N-2-吡啶基丁酰胺 (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,5R,6R)-5-(1-乙基丙氧基)-7-氧杂双环[4.1.0]庚-3-烯-3-羧酸乙基酯 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素(1-6) 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸

可以介绍下你们的产品么

你们是怎么收费的呢

可以开发票吗?